Champions Oncology Inc (OTCMKTS:CSBR) posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. The company had revenue of $3.72 million for the quarter. Champions Oncology had a negative return on equity of 215.50% and a negative net margin of 39.52%.
Shares of Champions Oncology (OTCMKTS:CSBR) traded up 1.4258% during trading on Wednesday, hitting $3.1442. 502 shares of the stock were exchanged. The firm has a 50 day moving average price of $2.80 and a 200 day moving average price of $2.93. Champions Oncology has a 52 week low of $1.11 and a 52 week high of $4.79. The firm’s market capitalization is $34.53 million.
WARNING: This piece of content was originally published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/champions-oncology-inc-csbr-posts-quarterly-earnings-results-updated-updated/1305523.html.
Separately, ValuEngine upgraded shares of Champions Oncology from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd.
A hedge fund recently raised its stake in Champions Oncology stock. GRT Capital Partners L.L.C. increased its position in shares of Champions Oncology Inc (OTCMKTS:CSBR) by 70.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,064 shares of the biotechnology company’s stock after buying an additional 17,000 shares during the period. GRT Capital Partners L.L.C. owned approximately 0.37% of Champions Oncology worth $106,000 at the end of the most recent reporting period.
About Champions Oncology
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with our FREE daily email newsletter.